Cargando…

Corrigendum: Expression of Human Epidermal Growth Factor Receptor-2 Status and Programmed Cell Death Protein-1 Ligand Is Associated With Prognosis in Gastric Cancer

Detalles Bibliográficos
Autores principales:	Lv, Huifang, Zhang, Junling, Sun, Keran, Nie, Caiyun, Chen, Beibei, Wang, Jianzheng, Xu, Weifeng, Wang, Saiqi, Liu, Yingjun, Chen, Xiaobing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8095244/ https://www.ncbi.nlm.nih.gov/pubmed/33959515 http://dx.doi.org/10.3389/fonc.2021.672599

Ejemplares similares

Expression of Human Epidermal Growth Factor Receptor-2 Status and Programmed Cell Death Protein-1 Ligand Is Associated With Prognosis in Gastric Cancer
por: Lv, Huifang, et al.
Publicado: (2021)

Dawning precision treatment for gastric cancer: The latest biomarkers
por: Sun, Keran, et al.
Publicado: (2021)

High DCR and Better Survival in Patients with Advanced or Metastatic Gastric Cancer Receiving Anti-Angiogenic TKI plus Chemotherapy: A Real-World Study
por: Nie, Caiyun, et al.
Publicado: (2023)

Molecular subtypes based on Wnt-signaling gene expression predict prognosis and tumor microenvironment in hepatocellular carcinoma
por: Xu, Weifeng, et al.
Publicado: (2022)

Microsatellite stable metastatic colorectal cancer without liver metastasis may be preferred population for regorafenib or fruquintinib plus sintilimab as third-line or above therapy:A real-world study
por: Nie, Caiyun, et al.
Publicado: (2022)

Clinical Study of Sintilimab as Second-Line or Above Therapy in Patients With Advanced or Metastatic Gastric Cancer: A Retrospective Study
por: Nie, Caiyun, et al.
Publicado: (2021)

Tailoring second-line or above therapy for patients with advanced or metastatic gastric cancer: A multicenter real-world study
por: Nie, Caiyun, et al.
Publicado: (2022)

Efficacy of regorafenib combined with PD-1 inhibitors in elderly patients with advanced metastatic colorectal cancer
por: Chen, Beibei, et al.
Publicado: (2022)

The efficacy and safety of apatinib treatment for patients with advanced or recurrent biliary tract cancer: a retrospective study
por: Nie, Caiyun, et al.
Publicado: (2021)

Clinical Study of Anlotinib as Third-Line or Above Therapy in Patients With Advanced or Metastatic Gastric Cancer: A Multicenter Retrospective Study
por: Nie, Caiyun, et al.
Publicado: (2022)

A PD-1 Inhibitor Induces Complete Response of Advanced Bladder Urothelial Carcinoma: A Case Report
por: Wang, Jianzheng, et al.
Publicado: (2021)

Combination of Anlotinib and Celecoxib for the Treatment of Abdominal Desmoid Tumor: A Case Report and Literature Review
por: Wang, Jianzheng, et al.
Publicado: (2022)

The Efficacy and Safety of Sintilimab Combined With Nab-Paclitaxel as a Second-Line Treatment for Advanced or Metastatic Gastric Cancer and Gastroesophageal Junction Cancer
por: Wang, Jianzheng, et al.
Publicado: (2022)

Knockdown of Kremen2 Inhibits Tumor Growth and Migration in Gastric Cancer
por: Chen, Beibei, et al.
Publicado: (2021)

Personalized Treatment of Advanced Gastric Cancer Guided by the MiniPDX Model
por: Wang, Jianzheng, et al.
Publicado: (2022)

Retrospective Study on the Efficacy and Safety of Pyrotinib-Based Therapy for HER2-Positive Nonbreast Advanced Solid Tumors
por: Wang, Jianzheng, et al.
Publicado: (2022)

Overview on the Role of E-Cadherin in Gastric Cancer: Dysregulation and Clinical Implications
por: Zhao, Huichen, et al.
Publicado: (2021)

MicroRNA-6884-5p Regulates the Proliferation, Invasion, and EMT of Gastric Cancer Cells by Directly Targeting S100A16
por: Lv, Huifang, et al.
Publicado: (2020)

Adding of apatinib and camrelizumab to overcome de novo trastuzumab resistance of HER2-positive gastric cancer: A case report and literature review
por: Lv, Huifang, et al.
Publicado: (2023)

EBV-Positive Gastric Cancer: Current Knowledge and Future Perspectives
por: Sun, Keran, et al.
Publicado: (2020)

Hypoxia-inducible factor 1-alpha expression correlates with response to neoadjuvant chemotherapy in women with breast cancer
por: Nie, Caiyun, et al.
Publicado: (2018)

Radiotherapy Upregulates Programmed Death Ligand-1 through the Pathways Downstream of Epidermal Growth Factor Receptor in Glioma
por: Song, Xing, et al.
Publicado: (2018)

Corrigendum: Relationship between programmed death ligand 1 expression and other clinicopathological features in a large cohort of gastric cancer patients
por: Chen, Xinhua, et al.
Publicado: (2023)

Ligand-Independent Epidermal Growth Factor Receptor Overexpression Correlates with Poor Prognosis in Colorectal Cancer
por: Yun, Sumi, et al.
Publicado: (2018)

MicroRNA-138-5p targets the NFIB-Snail1 axis to inhibit colorectal cancer cell migration and chemoresistance
por: Xu, Weifeng, et al.
Publicado: (2020)

Correction to: MicroRNA-138-5p targets the NFIB-Snail1 axis to inhibit colorectal cancer cell migration and chemoresistance
por: Xu, Weifeng, et al.
Publicado: (2020)

Correction for: TRIM29 mediates lung squamous cell carcinoma cell metastasis by regulating autophagic degradation of E-cadherin
por: Xu, Weifeng, et al.
Publicado: (2020)

TRIM29 mediates lung squamous cell carcinoma cell metastasis by regulating autophagic degradation of E-cadherin
por: Xu, Weifeng, et al.
Publicado: (2020)

DUSP4 directly deubiquitinates and stabilizes Smad4 protein, promoting proliferation and metastasis of colorectal cancer cells
por: Xu, Weifeng, et al.
Publicado: (2020)

Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma
por: Zhang, Yang, et al.
Publicado: (2014)

Programmed death‐ligand 1 is prognostic factor in esophageal squamous cell carcinoma and is associated with epidermal growth factor receptor
por: Zhang, Wencheng, et al.
Publicado: (2017)

Expression of Programmed Death Ligand-2 is associated with Prognosis in Nasopharyngeal Carcinoma Microenviroment
por: Li, Aixin, et al.
Publicado: (2022)

Association Between Intra-Tumoral Immune Response and Programmed Death Ligand 1 (PD-L1) in Gastric Cancer
por: Yan, Rong, et al.
Publicado: (2019)

Risk factors and prognosis of postoperative delirium in nonagenarians with hip fracture
por: Zhao, Shengjie, et al.
Publicado: (2023)

Expression of programmed death ligand-1 and programmed death-1 in samples of invasive ductal carcinoma of the breast and its correlation with prognosis
por: Zhou, Tingting, et al.
Publicado: (2018)

Expression of Programmed Cell Death-Ligands in Hepatocellular Carcinoma: Correlation With Immune Microenvironment and Survival Outcomes
por: Liao, Haotian, et al.
Publicado: (2019)

High Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma
por: Guo, Xiaofang, et al.
Publicado: (2018)

Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis
por: Zhang, Chen, et al.
Publicado: (2021)

Prognostic significance of epidermal growth factor receptor and programmed cell death-ligand 1 co-expression in esophageal squamous cell carcinoma
por: Jiang, Guoxiang, et al.
Publicado: (2023)

High Soluble Programmed Death-Ligand 1 Predicts Poor Prognosis in Patients with Nasopharyngeal Carcinoma
por: Lu, Tianzhu, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_djmcnqo6a3acn2q4pl76tuvbvg